Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
For Research Use Only This product is sold strictly for laboratory and in-vitro research by qualified professionals
Data availability All data used to build and validate models in addition to all peptide sequences designed and tested in this study are freely available for download from the code repository at Source data are provided with this paper
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
Tirzepatide (or Mounjaro) is currently being researched as an oral formulation and may be available soon
1.0 / 2.5 = 0.40 0.40 x 100 = 40 units Same dose
